Myeloma Drug Access Limits Unlikely Near-term – Aetna, Express Scripts Say
ICER’s cost-effectiveness assessment won't lead to place step therapy restrictions on sequence of multiple myeloma treatment regimens – at least until there's better data.
ICER’s cost-effectiveness assessment won't lead to place step therapy restrictions on sequence of multiple myeloma treatment regimens – at least until there's better data.